Identification
NameUracil mustard
Accession NumberDB00791  (APRD00130)
TypeSmall Molecule
GroupsApproved
Description

Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. [PubChem]

Structure
Thumb
Synonyms
5-(Di-2-chloroethyl)aminouracil
5-[Bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione
5-[Di(beta-chloroethyl)amino]uracil
5-Aminouracil mustard
5-N,N-Bis(2-chloroethyl)aminouracil
Aminouracil mustard
Uracil mustard
Uracil nitrogen mustard
Uramustine
External IDs NSC-34462 / U-8344
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Uracil Mustard Upjohn
Brand mixturesNot Available
Categories
UNIIW7KQ46GJ8U
CAS number66-75-1
WeightAverage: 252.098
Monoisotopic: 251.022832025
Chemical FormulaC8H11Cl2N3O2
InChI KeyIDPUKCWIGUEADI-UHFFFAOYSA-N
InChI
InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)
IUPAC Name
5-[bis(2-chloroethyl)amino]-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
ClCCN(CCCl)C1=CNC(=O)NC1=O
Pharmacology
Indication

Used for its antineoplastic properties.

Structured Indications Not Available
Pharmacodynamics

Uracil Mustard selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Uracil Mustard-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.

Mechanism of action

After activation, it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideunknown
intercalation
Humannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding

5%

MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Uracil mustard.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Uracil mustard.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Uracil mustard.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Uracil mustard.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Uracil mustard.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Uracil mustard.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Uracil mustard.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Uracil mustard.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Uracil mustard.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Uracil mustard.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
Manufacturers
  • Shire development inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)206 dec °CPhysProp
water solubility1070 mg/LNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.32 mg/mLALOGPS
logP0.79ALOGPS
logP0.41ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)9.05ChemAxon
pKa (Strongest Basic)1.61ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.44 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity58.35 m3·mol-1ChemAxon
Polarizability22.91 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8672
Blood Brain Barrier+0.7711
Caco-2 permeable-0.6657
P-glycoprotein substrateSubstrate0.5716
P-glycoprotein inhibitor INon-inhibitor0.7111
P-glycoprotein inhibitor IINon-inhibitor0.9146
Renal organic cation transporterNon-inhibitor0.63
CYP450 2C9 substrateNon-substrate0.7045
CYP450 2D6 substrateNon-substrate0.7938
CYP450 3A4 substrateNon-substrate0.5662
CYP450 1A2 substrateNon-inhibitor0.8493
CYP450 2C9 inhibitorNon-inhibitor0.6858
CYP450 2D6 inhibitorNon-inhibitor0.894
CYP450 2C19 inhibitorInhibitor0.5511
CYP450 3A4 inhibitorNon-inhibitor0.7064
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6569
Ames testAMES toxic0.718
CarcinogenicityNon-carcinogens0.9019
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity3.4851 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6391
hERG inhibition (predictor II)Non-inhibitor0.5087
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0w29-9730000000-047cc283312feb25a4edView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as nitrogen mustard compounds. These are compounds having two beta-haloalkyl groups bound to a nitrogen atom.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic nitrogen compounds
Sub ClassOrganonitrogen compounds
Direct ParentNitrogen mustard compounds
Alternative ParentsDialkylarylamines / Pyrimidones / Aminopyrimidines and derivatives / Hydropyrimidines / Vinylogous amides / Heteroaromatic compounds / Ureas / Lactams / Azacyclic compounds / Organopnictogen compounds
SubstituentsNitrogen mustard / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aminopyrimidine / Pyrimidone / Hydropyrimidine / Pyrimidine / Heteroaromatic compound / Vinylogous amide / Lactam
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsnitrogen mustard, aminouracil (CHEBI:9884 )

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
Actions
intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hartley JA, Forrow SM, Souhami RL: Effect of ionic strength and cationic DNA affinity binders on the DNA sequence selective alkylation of guanine N7-positions by nitrogen mustards. Biochemistry. 1990 Mar 27;29(12):2985-91. [PubMed:2337578 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:53